II. Pathophysiology: Mechanism
-
Sodium Channel Blocker
- Slows Myocyte depolarization (QRS Widening, Prolonged QTc, Hypotension)
- Alpha Adrenergic Blocker (alpha-1 receptor blockers)
- Sedation, Miosis and Orthostatic Hypotension
-
Serotonin Norepinephrine Reuptake Inhibitor
- Initial Tachycardia and Hypertension after acute ingestion
- May be followed by Hypotension with Norepinephrine depletion
- Antimuscarinic Anticholinergic effects
- Sedation
III. Pharmacokinetics: Tricyclic Antidepressant
- Peak concentrations 2-8 hours after ingestion
- Highly lipophilic
- High volume of distribution
- High Protein binding
- Hepatic metabolism
IV. Findings
- See Anticholinergic Toxicity (muscarinic Anticholinergic effects)
- Symptoms and Signs typically at ingestions >5 mg/kg (and typical onset within 2 hours of ingestion)
- Altered Level of Consciousness
- Hypotension
- Acute Respiratory Distress Syndrome
- Seizures (esp. when QRS Duration >100 ms)
- Tachycardia
- Urinary Incontinence
V. Diagnostics: EKG Findings
-
R Wave in aVR (elevation of the terminal 40 msec)
- Tall R Wave in aVR (>3 mm, R/S ratio >0.7) suggests Right Ventricular Strain
- Right Axis Deviation
-
QRS Widening >0.1 s
- Also seen with Cocaine and Diphenhydramine
- QRS >0.16 s is associated with Seizures and Dysrhythmias
- Mortality increases with QRS Duration
- Emergent management with Sodium Bicarbonate alkalinization targets the QRS width
- QTc Prolongation (440 to 460 msec)
-
Sinus Tachycardia
- Due to Anticholinergic and Sympathomimetic effects
- Bradycardia may occur with severe toxicity
- Ventricular Dysrhythmia (e.g. Torsades de Pointes)
- Right Bundle Branch Block may be present
VI. Differential Diagnosis: Sodium Channel Blocker Toxicity
- Cardiovascular
- Gastrointestinal: Phenothiazines
- Neurologic
- Bupivicaine (See LAST Reaction)
- Carbamazepine Poisoning
- Diphenhydramine (Anticholinergic Poisoning)
- Psychiatric: Antidepressants
- Infectious Disease: Anti-Malarials
- Miscellaneous
- References
- Berberian (2024) Crit Dec Emerg Med 38(4): 12-3
VII. Labs
- See Unknown Ingestion
-
Venous Blood Gas (VBG)
- Obtain serial levels until stabilized
- Toxicology labs
- Comprehensive Metabolic Panel
- Serum Acetaminophen Level
- Serum Salicylate Level
- Urine Drug Screen
- Avoid Tricyclic Antidepressant levels
- TCA levels are send-out labs that do not assist in acute management
VIII. Precautions
- Tricyclic Antidepressant Overdose have a high risk of mortality
- Even "One Pill Can Kill" (doses >15 mg/kg)
- Avoid provocative agents
- Avoid Physostigmine
- Avoid Class IA Antiarrhythmics (e.g. Procainamide, Quinine)
- Avoid Class IC Antiarrhythmics
- Avoid Barbiturates and Phenytoin (see Seizures below)
- Avoid reducing Heart Rate
- Tachycardia decreases the QT Interval and is protective against Torsades de Pointes
IX. Management: General
- Significant risk with ingestions >10 mg/kg
- Intubate early in serious Tricyclic Overdose (due to rapid decompensation)
- Succinylcholine is preferred paralytic (unless Hyperkalemia) less Respiratory Acidosis than with longer acting agent
-
Gastric Decontamination if early presentation
- Give Activated Charcoal if presenting in first 1 hour of ingestion and airway protected
- Disposition: Asymptomatic Ingestions <5 mg/kg
- Medically cleared if normal ekg and asymptomatic at 6 hours
X. Management: Neurologic
- Avoid Antipsychotics (may worsen cardiac conduction)
-
Seizures
- Benzodiazepines: Lorazepam (Ativan)
- Avoid Barbiturates
- Avoid Phenytoin (Dilantin)
- Propofol may be used for refractory Seizures
XI. Management: Prolonged QRS interval (>0.1 s)
- Background
- Sodium Bicarbonate mechanism
- Alkalinize blood and increases drug binding, volume of distribution and drug urinary excretion
- Sodium loading helps to overcome the TCA blocking of the Sodium channels
- Even multiple repeat doses of Sodium Bicarbonate are safe
- Unlikely to causes significant Hypernatremia or Metabolic Alkalosis
- Monitor for Electrolyte abnormalities with high Sodium Bicarbonate dosing
- Sodium Bicarbonate mechanism
- Children
- Sodium Bicarbonate 1-2 mEq/kg up to 50 mEq bolus, and initiate infusion
- Adults
- Sodium Bicarbonate
- Start: 2-4 ampules
- Titrate: 2 ampules every 2-5 minutes until QRS narrows (may require 15-20 ampules)
- May initiate Sodium Bicarbonate isotonic Sodium Bicarbonate maintenance infusion when stable
- Goal VBG pH 7.45 to 7.50 (no higher than 7.55)
- May substitute Sodium acetate if inadequate supply of Sodium Bicarbonate
- Other adjunctive measures
- Consider Intralipid
- Hypertonic Saline 3% 1-2 mEq/kg IV
- Second-line if QRS prolongation is refractory to Sodium Bicarbonate
- Lidocaine (Class IB Antiarrhythmic)
- Fast association and dissociation allows displacement of TCA from cardiac cells
- Results in increased repolarization time and QRS narrowing
- Dosing: 1.5 mg/kg per dose
- Ventilator
- Maintain standard Tidal Volumes (6-8 ml/kg) at an increased Respiratory Rate (at least 16-18 bpm)
- Adjust Respiratory Rate to a goal VBG pH 7.45 to 7.55
- Activated Charcoal
- Risk of aspiration even when intubated (do not give unless intubated with cuffed tube)
- Indicated in refractory QRS Widening to numerous bicarbonate ampules (e.g. more than 10 ampules)
- Suggests continued Tricyclic Antidepressant absorption (esp. if decreased GI motility)
- Sodium Bicarbonate
XII. Management: Hypotension
- Tricyclic Antidepressants is an alpha blocker and results in Hypotension
- Goal: Low to normal Blood Pressure and adquate critical end-organ perfusion
- Intravenous Fluids
-
Vasopressors
- Dopamine is NOT recommended as may exacerbate tricyclic beta mediated effects
- Norepinephrine 4 mg/500 cc D5W at 0.1 to 0.2 mcg/kg/min
- Adults: 8-12 mcg/min
- Children: <6 mcg/min
- Other measures
- Consider extracorporal membrane oxygenation (ECMO)
- Consider intra-aortic balloon pump
XIII. References
- (2016) CALS Manual, 14th ed, 1:132-3
- Masom (2017) Crit Dec Emerg Med 31(11): 24
- Swadron and Nordt in Herbert (2013) EM:Rap 13(3):5-7
- Thapar, Orantes and Miller (2022) Crit Dec Emerg Med 36(2): 19-24
- Henry (2006) Pediatr Clin North Am 53(2): 293-315 [PubMed]
- Vega (2024) Am Fam Physician 109(2): 143-53 [PubMed]